Actively Recruiting
68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer
Led by Peking University First Hospital · Updated on 2026-04-02
30
Participants Needed
1
Research Sites
134 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to investigate and evaluate the safety and performance of a novel probe, PFD3, for the diagnosis and assessment of patients with small cell lung cancer (SCLC).
CONDITIONS
Official Title
68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults
- Histologically confirmed small cell lung cancer (SCLC)
- At least one measurable lesion 51 cm in diameter (primary tumor, metastatic lesion, or involved lymph node) confirmed by standard imaging
- Laboratory tests (complete blood count and biochemical analysis) completed within 4 weeks prior to enrollment
You will not qualify if you...
- Pregnancy
- Breastfeeding
- Acute psychiatric disorders
- Inability to undergo PET scanning (e.g., claustrophobia, weight limits, or other medical contraindications)
- Inability to complete study procedures as anticipated
- Prior therapy targeting DLL3
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking university first hospital nuclear medicine
Beijing, Beijing Municipality, China, 100034
Actively Recruiting
Research Team
T
Tingting Yuan, M. D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here